Immuron Announces Sales (Unaudited) Of Travelan A$1.5M, Up 13% Prior Quarter, An OTC Immune Supplement Targeting Pathogenic Bacteria And Toxins Produced In The Gastrointestinal Tract

Benzinga · 10/15 10:09
Global • September 2024 Quarter AUD$1.5 million up 13% on prior quarter



 
Australia

 
• September 2024 Quarter AUD$1.0 million up 3% on prior quarter



 
North

America

 
• September 2024 Quarter AUD$0.5 million up 48% on prior quarter